Parathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose | Zendy

Mara J. Horwitz | Zendy; Mary Beth Tedesco | Zendy; Adolfo GarcíaOcaña | Zendy; Susan M. Sereika | Zendy; Linda Prebehala | Zendy; Alessandro Bisello | Zendy; Bruce W. Hollis | Zendy; Caren M. Gundberg | Zendy; Andrew F. Stewart | Zendy

Open Access

Parathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose

Author(s) -

Mara J. Horwitz,

Mary Beth Tedesco,

Adolfo GarcíaOcaña,

Susan M. Sereika,

Linda Prebehala,

Alessandro Bisello,

Bruce W. Hollis,

Caren M. Gundberg,

Andrew F. Stewart

Publication year - 2010

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2009-0233

Subject(s) - anabolism , medicine , endocrinology , bone resorption , parathyroid hormone , placebo , bone remodeling , osteoporosis , adverse effect , parathyroid hormone related protein , calcium , alternative medicine , pathology

PTH is the only approved skeletal anabolic agent for the treatment of human osteoporosis. Unlike PTH, which is a mixed anabolic and catabolic agent, PTHrP displays features suggesting that it may be a pure anabolic agent when intermittently administered. The full dose range of PTHrP is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research